Jefferies analyst Kaumil Gajrawala upgraded Clorox Company CLX to Buy from Hold, raising the price forecast to $187 from $174. The analyst projects that Clorox will return to its former status as a company delivering peer-leading economic profit growth and returns on capital. Historically, this performance has warranted a valuation premium of 30% compared to its peers. According to the analyst, topline growth is already showing signs of improvement, and operating leverage is becoming increasingly attainable ...